« Return to News | Awards & Advancement

PharmaNet/i3 names VP and general manager, neuroscience

Monday, July 16, 2012 11:05 AM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.

Dr. Lasser, board-certified by the American Board of Psychiatry and Neurology, has more than 18 years of experience in medical practice and the pharmaceutical industry. He joins PharmaNet/i3 from Shire Pharmaceuticals, where he served as general manager for VYVANSE New Uses in multiple central nervous system (CNS) indications. Previously he served as Shire’s senior director in clinical development-medical affairs, overseeing clinical, medical and scientific input to the lifecycle for CNS therapeutics.

He also has held positions of increasing seniority at leading pharmaceutical companies where he directed global CNS medical strategy and clinical studies, and before that was in private practice and held several positions in adult and geriatric psychotherapy and psychopharmacology.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.